Nurix Therapeutics, Inc.
NRIX
$13.59
$0.403.03%
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -12.37% | -31.84% | -60.58% | 30.74% | 123.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -12.37% | -31.84% | -60.58% | 30.74% | 123.49% |
| Cost of Revenue | 35.22% | 15.93% | 6.90% | 9.14% | 7.82% |
| Gross Profit | -56.10% | -45.95% | -144.12% | -0.87% | 12.13% |
| SG&A Expenses | -0.58% | 10.31% | 0.27% | 20.14% | 15.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.84% | 14.91% | 5.56% | 11.08% | 9.05% |
| Operating Income | -42.62% | -36.49% | -81.36% | -5.28% | 6.89% |
| Income Before Tax | -39.53% | -32.16% | -83.12% | -1.71% | 10.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -39.55% | -32.38% | -83.49% | -1.93% | 10.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.55% | -32.38% | -83.49% | -1.93% | 10.19% |
| EBIT | -42.62% | -36.49% | -81.36% | -5.28% | 6.89% |
| EBITDA | -41.54% | -37.19% | -85.81% | -4.79% | 7.19% |
| EPS Basic | 2.70% | 1.06% | -59.61% | -0.31% | 11.39% |
| Normalized Basic EPS | 2.71% | 1.25% | -59.30% | -0.08% | 11.40% |
| EPS Diluted | 2.70% | 1.06% | -59.61% | -0.31% | 11.39% |
| Normalized Diluted EPS | 2.71% | 1.25% | -59.30% | -0.08% | 11.40% |
| Average Basic Shares Outstanding | 43.42% | 33.81% | 14.96% | 1.62% | 1.35% |
| Average Diluted Shares Outstanding | 43.42% | 33.81% | 14.96% | 1.62% | 1.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
